Skye Bioscience posts corporate presentation on nimacimab obesity drug development strategy

Skye Bioscience

Skye Bioscience

SKYE

0.00
  • Skye Bioscience investor deck highlighted clinical combination data for obesity program pairing peripheral CB1 antibody nimacimab with semaglutide.
  • CBeyond readout showed 3% incremental weight loss versus semaglutide alone at 26 weeks.
  • Mean weight loss reached 22.3% at 52 weeks, with no plateau observed.
  • Safety summary cited no nimacimab-associated neuropsychiatric signal through 52 weeks, with no additive gastrointestinal burden versus semaglutide.
  • Development update flagged 200 mg weekly nimacimab monotherapy as underexposed in peripheral tissues, with a higher-dose expansion study under way to increase exposure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.